Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 38Neoplasm Metastasis 14Liver Neoplasms 11Colorectal Neoplasms 11Cholangiocarcinoma 9Pancreatic Neoplasms 8Lung Neoplasms 8Colonic Neoplasms 7Breast Neoplasms 7Thyroid Nodule 6Recurrence 6Carcinoma, Renal Cell 6Carcinoma, Non-Small-Cell Lung 6Thyroid Neoplasms 5Rectal Neoplasms 4Neoplasms 4Esophageal Neoplasms 4Prostatic Neoplasms 3Pain 3Kidney Neoplasms 3Barrett Esophagus 3Agnosia 3Thyroid Diseases 2Thyroid Cancer, Papillary 2Leiomyoma 2Hyperaldosteronism 2Gallbladder Neoplasms 2Cancer Pain 2Bile Duct Neoplasms 2Adrenocortical Adenoma 2

Interventions

Radiofrequency Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Multiple Advanced Tumors After PD-1 Therapy Failure × Radiofrequency Ablation × Clear all
NCT07095803 2025-07-31

Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure

Fudan University

Phase 2 Not yet recruiting
60 enrolled

Multiple Advanced Tumors After PD-1 Therapy Failure

Data powered by HemOnc (CC BY 4.0) Colophon âš¡